A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

NCT02302339 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

132

Enrollment

INDUSTRY

Sponsor class

Stopped Development of glembatumumab vedotin was discontinued

Conditions

Melanoma

Interventions

DRUG: glembatumumab vedotin
DRUG: glembatumumab vedotin and varlilumab
DRUG: glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)
DRUG: glembatumumab vedotin and CDX-301

Sponsor

Celldex Therapeutics